- Home
- ALKT vs ADMA Comparison
ALKT vs ADMA Comparison
Compare ALKT & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- ADMA
- Stock Information
- Founded
- ALKT 2007
- ADMA 2004
- Country
- ALKT United States
- ADMA United States
- Employees
- ALKT N/A
- ADMA N/A
- Industry
- ALKT EDP Services
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALKT Technology
- ADMA Health Care
- Exchange
- ALKT Nasdaq
- ADMA Nasdaq
- Market Cap
- ALKT 3.3B
- ADMA 3.8B
- IPO Year
- ALKT 2021
- ADMA N/A
- Fundamental
- Price
- ALKT $31.14
- ADMA $15.84
- Analyst Decision
- ALKT Buy
- ADMA Strong Buy
- Analyst Count
- ALKT 7
- ADMA 4
- Target Price
- ALKT $43.71
- ADMA $21.25
- AVG Volume (30 Days)
- ALKT 522.7K
- ADMA 2.1M
- Earning Date
- ALKT 02-27-2025
- ADMA 03-03-2025
- Dividend Yield
- ALKT N/A
- ADMA N/A
- EPS Growth
- ALKT N/A
- ADMA N/A
- EPS
- ALKT N/A
- ADMA 0.28
- Revenue
- ALKT $315,562,000.00
- ADMA $382,809,000.00
- Revenue This Year
- ALKT $28.56
- ADMA $66.90
- Revenue Next Year
- ALKT $24.23
- ADMA $13.76
- P/E Ratio
- ALKT N/A
- ADMA $56.45
- Revenue Growth
- ALKT 26.73
- ADMA 63.39
- 52 Week Low
- ALKT $22.65
- ADMA $5.08
- 52 Week High
- ALKT $42.29
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- ALKT 28.33
- ADMA 39.58
- Support Level
- ALKT $32.48
- ADMA $15.60
- Resistance Level
- ALKT $33.74
- ADMA $16.67
- Average True Range (ATR)
- ALKT 1.14
- ADMA 0.64
- MACD
- ALKT -0.30
- ADMA 0.02
- Stochastic Oscillator
- ALKT 4.40
- ADMA 24.44
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. Alkami Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency with the support of a proprietary, true cloud-based, multi-tenant architecture.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.